{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:40:51Z","timestamp":1783021251292,"version":"3.54.6"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jcf.2024.02.008","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T16:15:07Z","timestamp":1709568907000},"page":"685-689","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical efficacy of CFTR modulator therapy in people with cystic fibrosis carrying the I1234V mutation"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-427X","authenticated-orcid":false,"given":"Bat El Bar","family":"Aluma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2565-4185","authenticated-orcid":false,"given":"Joel","family":"Reiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Efrati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2964-4689","authenticated-orcid":false,"given":"Yael","family":"Bezalel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomit","family":"Keler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Ashkenazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Dagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Buchnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2293-0212","authenticated-orcid":false,"given":"Ido","family":"Sadras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malena","family":"Cohen-Cymberknoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2024.02.008_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-022-02350-5","article-title":"The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis","volume":"17","author":"Costa","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"10.1016\/j.jcf.2024.02.008_bib0002","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del\u2013gating and\u2013residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.02.008_bib0003","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2024.02.008_bib0004","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2024.02.008_bib0005","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jcf.2022.01.012","article-title":"Sustained effectiveness of Elexacaftor-Tezacaftor-Ivacaftor in lung transplant candidates with cystic fibrosis","volume":"21","author":"Martin","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.02.008_bib0006","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1164\/rccm.202102-0509OC","article-title":"A phase 3 open-label study of Elexacaftor\/Tezacaftor\/Ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele","volume":"203","author":"Zemanick","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.02.008_bib0007","doi-asserted-by":"crossref","DOI":"10.1089\/ped.2023.0020","article-title":"New for 2022: food and drug administration approvals of pediatric respiratory medications","author":"Bickel","year":"2023","journal-title":"Pediatr Allergy Immunol Pulmonol"},{"key":"10.1016\/j.jcf.2024.02.008_bib0008","series-title":"TRIKAFTA prescribing information","year":"2021"},{"issue":"9","key":"10.1016\/j.jcf.2024.02.008_bib0009","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1164\/rccm.201901-0145OC","article-title":"Correlating cystic fibrosis transmembrane conductance regulator function with clinical features to inform precision treatment of cystic fibrosis","volume":"199","author":"McCague","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2024.02.008_bib0010","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jcf.2022.12.007","article-title":"Lived experiences of people with cystic fibrosis that were not eligible for Elexacaftor-Tezacaftor-Ivacaftor (ETI): a qualitative study","volume":"22","author":"Milo","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2024.02.008_bib0011","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jcf.2022.10.011","article-title":"Treatment effects of Elexacaftor\/Tezacaftor\/Ivacaftor in people with CF carrying non-F508del mutations","volume":"22","author":"Livnat","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.02.008_bib0012","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jcf.2015.02.002","article-title":"Comparative ex vivo, in vitro and in silico analyses of a CFTR splicing mutation: importance of functional studies to establish disease liability of mutations","volume":"15","author":"Ramalho","year":"2016","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.02.008_bib0013","series-title":"Biochemical interrogation of rare cystic fibrosis mutations informs strategies for future therapeutic intervention","author":"Molinski","year":"2016"},{"issue":"8","key":"10.1016\/j.jcf.2024.02.008_bib0014","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/gim.2014.4","article-title":"Genetic, cell biological, and clinical interrogation of the CFTR mutation c. 3700 A>G (p. Ile1234Val) informs strategies for future medical intervention","volume":"16","author":"Molinski","year":"2014","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.jcf.2024.02.008_bib0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3390\/jpm10040209","article-title":"Preclinical studies of a rare CF-causing mutation in the second nucleotide binding domain (c. 3700A>G) show robust functional rescue in primary nasal cultures by novel CFTR modulators","volume":"10","author":"Laselva","year":"2020","journal-title":"J Pers Med"},{"issue":"1","key":"10.1016\/j.jcf.2024.02.008_bib0016","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02426-2019","article-title":"Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis","volume":"57","author":"Ramalho","year":"2021","journal-title":"Eur Respirat J"},{"issue":"3","key":"10.1016\/j.jcf.2024.02.008_bib0017","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jcf.2020.07.003","article-title":"CFTR modulator therapy for cystic fibrosis caused by the rare c. 3700A>G mutation","volume":"20","author":"Phuan","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"1","key":"10.1016\/j.jcf.2024.02.008_bib0018","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/02724939992671","article-title":"Geographic distribution of cystic fibrosis transmembrane regulator gene mutations in Saudi Arabia","volume":"19","author":"Banjar","year":"1999","journal-title":"Ann Trop Paediatr"},{"key":"10.1016\/j.jcf.2024.02.008_bib0019","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s40142-019-00174-7","article-title":"An overview of the homozygous cystic fibrosis transmembrane conductance regulator mutation c. 3700 A>G (p. Ile1234Val) in Qatar","volume":"7","author":"Hammoudeh","year":"2019","journal-title":"Curr Genet Med Rep"},{"key":"10.1016\/j.jcf.2024.02.008_bib0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4081\/mrm.2019.30","article-title":"Approaching two decades of cystic fibrosis research in Qatar: a historical perspective and future directions","volume":"14","author":"Hammoudeh","year":"2019","journal-title":"Multidiscip Respir Med"},{"key":"10.1016\/j.jcf.2024.02.008_bib0021","article-title":"Phenotypic and molecular characteristics of CF patients carrying the I1234V mutation","volume":"170","author":"Aluma","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.jcf.2024.02.008_bib0022","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","article-title":"Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation","volume":"181","author":"Farrell","year":"2017","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.jcf.2024.02.008_bib0023","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/02724936.2000.11748135","article-title":"Cystic fibrosis in a large kindred family in Qatar","volume":"20","author":"Wahab","year":"2000","journal-title":"Ann Trop Paediatr"},{"issue":"6","key":"10.1016\/j.jcf.2024.02.008_bib0024","doi-asserted-by":"crossref","first-page":"527","DOI":"10.4103\/lungindia.lungindia_39_17","article-title":"The emergence of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis patients on inhaled antibiotics","volume":"34","author":"AbdulWahab","year":"2017","journal-title":"Lung India"},{"issue":"17","key":"10.1016\/j.jcf.2024.02.008_bib0025","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445\u2013Tezacaftor\u2013Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jcf.2024.02.008_bib0026","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jcf.2024.02.008_bib0027","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2024.02.008_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2023.06.001","article-title":"Clinical and functional efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis carrying the N1303K mutation","author":"Sadras","year":"2023","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2024.02.008_bib0029","article-title":"The French compassionate programme of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","volume":"61","author":"Burgel","year":"2023","journal-title":"Eur Respirat J"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324000195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T19:07:16Z","timestamp":1783019236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324000195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1569199324000195"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.02.008","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy of CFTR modulator therapy in people with cystic fibrosis carrying the I1234V mutation","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}